Skip Navigation

Lotus Reported Unaudited February Revenues of NT$1,052 Million

08 March 2024

Taipei, Taiwan, March 08, 2024 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical company headquartered in Taiwan, has disclosed its unaudited consolidated revenue for February 2024, reaching NT$1,052 million.

In February, the Asian market experienced a slowdown due to the new year holidays in Taiwan and Korea, coupled with no new product launches in Southeast Asian countries. Export revenue remained at a similar level compared to the same period last year.

Moving forward, Lotus is positioned to maintain consistent expansion in both the Asian and export markets throughout 2024. The firm remains steadfast in its endeavor to broaden its range of New Chemical Entities (NCE), 505(b)(2), and biosimilars, demonstrating a strong commitment to fostering sustainable growth across all aspects of its business operations.


About Lotus

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. The Company has a recognized best-in-class R&D and manufacturing platform in Asia and has established partnerships in nearly every global market including the U.S., Europe, Japan, China, and Brazil. Lotus runs over 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US, with over 250 commercial products. The Company invests in diversified best portfolio consisting of high-barrier oncology, complex generics as well as 505(b)2 and NCE via internal R&D investment and licensing-in partnership, and also strengthens its portfolio competitiveness by adding biosimilar products with support from strategic partners. Its industry-leading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.

Media Enquiries:

Yu-ying Yang, associate Director, Corporate Communication.

+886 2 2700 5908